ELINEST Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Elinest, and when can generic versions of Elinest launch?
Elinest is a drug marketed by Novast Labs Ltd and is included in one NDA.
The generic ingredient in ELINEST is ethinyl estradiol; norgestrel. There are twenty-six drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norgestrel profile page.
US Patents and Regulatory Information for ELINEST
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novast Labs Ltd | ELINEST | ethinyl estradiol; norgestrel | TABLET;ORAL-28 | 091105-001 | Mar 28, 2012 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
